1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Washington >
  6. TuHURA Biosciences Acquires Kineta

M&A Deal Summary

TuHURA Biosciences Acquires Kineta

On June 23, 2025, TuHURA Biosciences acquired life science company Kineta

Acquisition Highlights
  • This is TuHURA Biosciences’ 1st transaction in the Life Science sector.
  • This is TuHURA Biosciences’ 1st transaction in the United States.
  • This is TuHURA Biosciences’ 1st transaction in Washington.

M&A Deal Summary
Date 2025-06-23
Target Kineta
Sector Life Science
Buyer(s) TuHURA Biosciences
Deal Type Merger

Target

Kineta

Mercer Island, Washington, United States
Kineta is a clinical-stage biotechnology company that develops immunotherapies to transform patients’ lives. it is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kineta is based in Mercer Island, Washington.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

TuHURA Biosciences

Tampa, Florida, United States
Category Company
Sector Life Science
DESCRIPTION

TuHURA Biosciences is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA Biosciences is based in Tampa, Florida.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: Washington M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal